1-(cyclopentylmethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one | 1021915-39-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-(cyclopentylmethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one
• 英文别名: 1-Cyclopentylmethyl-6-quinolin-5-yl-1,3-dihydro-imidazo[4,5-b]pyrazin-2-one；3-(cyclopentylmethyl)-5-quinolin-5-yl-1H-imidazo[4,5-b]pyrazin-2-one
• CAS: 1021915-39-8
• 化学式: C₂₀H₁₉N₅O
• 分子量: 345.404
• InChiKey: SDSKKSXAVZBIAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  71
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(cyclopentylmethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one 、 、 环戊基甲胺盐酸盐 、 三乙胺 以 乙醇 为溶剂， 以to give 25 mg (36% yield) of white solid的产率得到1-Cyclopentylethyl-6-quinolin-5-YL-1,3-dihydro-imidazo[4,5-B]pyrazin-2-one
  参考文献：
  名称：

  Methods of treatment comprising the administration of heteroaryl compounds

  摘要：

  本文提供具有以下结构的杂环芳基化合物：其中R1、R2、L、X、Y、Z、Q、A和B的定义如下，包括有效量的杂环芳基化合物的组合物以及治疗或预防癌症、炎症疾病、免疫疾病、代谢疾病以及通过抑制激酶通路治疗或预防的疾病的方法，包括向需要的患者投与有效量的杂环芳基化合物。

  公开号：

  US08372976B2
• 作为产物：
  描述：

  N-bis-boc-3-bromo-5-(quinoline-5-yl)-pyrazin-2-ylamine 、 环戊基甲胺盐酸盐 在 三乙胺 作用下， 以 乙醇 为溶剂， 以36%的产率得到1-(cyclopentylmethyl)-6-(quinolin-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one
  参考文献：
  名称：

  WO2008/51493

  摘要：

  公开号：

文献信息

• Heteroaryl compounds, compositions thereof, and methods of treatment therewith
  申请人：Mortensen Deborah Sue

  公开号：US20090023724A1

  公开（公告）日：2009-01-22

  Provided herein are Heteroaryl Compounds having the following structure: wherein R 1 , R 2 , L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

  本文提供具有以下结构的杂环芳基化合物：其中R1，R2，L，X，Y，Z，Q，A和B的定义如下，包括有效量的杂环芳基化合物的组合物以及治疗或预防癌症，炎症状况，免疫状况，代谢状况以及通过抑制激酶通路可治疗或预防的状况的方法，包括向需要治疗的患者中给予有效量的杂环芳基化合物。
• METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS
  申请人：Mortensen Deborah Sue

  公开号：US20110245245A1

  公开（公告）日：2011-10-06

  Provided herein are Heteroaryl Compounds having the following structure: wherein R 1 , R 2 , L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

  本文提供了具有以下结构的杂环芳基化合物：其中R1、R2、L、X、Y、Z、Q、A和B的定义如下，包括有效量的杂环芳基化合物的组合物，并且治疗或预防癌症、炎症状况、免疫病状况、代谢病状况和通过抑制激酶途径可治疗或预防的病状况的方法包括向需要治疗的患者中施用有效量的杂环芳基化合物。
• IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS
  申请人：Signal Pharmaceuticals, LLC

  公开号：EP2992878A1

  公开（公告）日：2016-03-09

  The invention provides a TOR kinase inhibitor for use in a method for treating non-small cell lung carcinoma, cervical cancer or Peutz-Jeghers Syndrome, wherein the method comprises administering the TOR kinase inhibitor to a patient having non-small cell lung carcinoma, cervical cancer or Peutz-Jeghers Syndrome characterized by a LKB1 gene or protein loss or mutation, relative to wild type, wherein the TOR kinase inhibitor is 1-ethyl-7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, or tautomer thereof. The TOR kinase inhibitor can be used use in a method for treating non-small cell lung carcinoma, cervical cancer or Peutz-Jeghers Syndrome, wherein the the TOR kinase inhibitor is administered in combination with one or more agents selected from 2-deoxyglucose, metformin, phenformin and pemetrexed. The TOR kinase inhibitor can further be used for predicting the likelihood of a patient having non-small cell lung carcinoma, cervical cancer or Peutz-Jeghers Syndrome being responsive to TOR kinase inhibitor therapy.

  本发明提供一种TOR激酶抑制剂，用于治疗非小细胞肺癌、宫颈癌或Peutz-Jeghers综合征的方法，其中该方法包括向患有非小细胞肺癌、宫颈癌或Peutz-Jeghers综合征的患者施用TOR激酶抑制剂、其中TOR激酶抑制剂是1-乙基-7-(2-甲基-6-(4H-1,2,4-三唑-3-基)吡啶-3-基)-3,4-二氢吡嗪并[2,3-b]吡嗪-2(1H)-酮或其药学上可接受的盐、螯合物、溶胶、立体异构体或同系物。TOR激酶抑制剂可用于治疗非小细胞肺癌、宫颈癌或Peutz-Jeghers综合征的方法中，其中TOR激酶抑制剂与一种或多种选自2-脱氧葡萄糖、甲福明、苯福明和培美曲塞的药物联合给药。TOR激酶抑制剂还可用于预测非小细胞肺癌、宫颈癌或佩兹-杰格综合征患者对TOR激酶抑制剂治疗产生反应的可能性。
• Treatment of cancer with TOR kinase inhibitors
  申请人：Signal Pharmaceuticals, LLC

  公开号：US11166950B2

  公开（公告）日：2021-11-09

  Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.

  本文提供了治疗或预防患者实体瘤、非霍奇金淋巴瘤或多发性骨髓瘤的方法，包括向患有实体瘤、非霍奇金淋巴瘤或多发性骨髓瘤的患者施用有效量的TOR激酶抑制剂。
• HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
  申请人：Signal Pharmaceuticals LLC

  公开号：EP2078016B1

  公开（公告）日：2012-02-01